Overall, these studies demonstrate the importance of understanding the mechanisms that are activated upon relief of ERK1/2-dependent negative feedback, as those efficiently promote drug resistance, particularly in B-RafV600E tumours. The gene discussed is MAPK3; the disease is neoplasm.